参考文献/References:
[1] Chiu WC, Gann DS, Darlington DN.Measuring plasminogen activator inhibitor activity in plasma by two enzymatic assays[J].J Biochem Biophys Methods, 2000, 45(2):127-140.
[2] van Baal WM, Emeis JJ, van der Mooren M J, et al.Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebocontrolled 12-week study[J].Thromb Haemost, 2000, 83(1):29-34.
[3] Ince B, Bayram C, Harmanci H, et al.Hemostatic markers in ischemic stroke of undetermined etiology[J].Thromb Res, 1999, 96(3):169-174.
[4] Hong JJ.Hereditary defects in fibrinolysis associated with thrombosis[J].Semin Thromb Hemost, 1999, 25(3):321-331.
[5] Prisco D, Conti AA, Giurlani L.Clinical application of fibrinolysis laboratory tests:a review[J].Ann Ital Med Iht, 1998, 13(2):81-87.
[6] Ferrier CM, Sucin S, van Geloof WL, et al.Hight PA-expression in primary melanoma of the limb correlates with good prognosis[J].Br J Cancer, 2000, 83(10):1351-1359.
[7] Angles-Cano E.Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process[J].Braz J Med Biol Res, 1997, 30(11):1271-1280.
[8] Mustonen P, Lepantalo M, Lassila R.Physical exertion induces thrombinformation and fibrin degradation in patients with peripheral atherosclerosis[J].Arterioscler Thromb Vasc Biol, 1998, 18(2):244-249.
[9] Chang LC, Meyerhoff ME, Yang VC.Electrochemical assay of plasminogen activators in plasma using polyion-sensitive membrane electro detection[J].Anal Biochem, 1999, 276(1):8-12.
[10] Gunther A, Markart P.Kalinowski M, et al.Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents.Kinetics of lysis and rescue of surface acivity[J].Am J Respir Cell Mol Biol, 1999, 21(6):738-745.
[11] Michels HR, Hoffman JJ, Bar FW.Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infaretion:comparison of infusion, single-bolus, and split-bolus administration[J].J Thromb Thrombolysis, 1999, 8(3):213-221.
[12] Edelberg JM, Pizzo SV.Lipoprotein(a) in the regulation of fibrinolysis[J].J Atheroscler Thromb, 1995, 2:S5-S7.
[13] Mitropoulos KA.Lipid-thrombosis interfoce[J].Br Med Bull, 1994, 50(4):813-832.
[14] Redlitz A, Plow EF.Receptors for plasminogen and t-PA:an update[J].Baillieres Clin Haematol, 1995, 8(2):313-327.
[15] Bell WR.The fibrinolytic system in neoplasia[J].Semin Thromb Hemost, 1996, 22(6):459-478.
[16] Ikeda U, Yamamoto K, Shimada K.Biochemical markers of coagulation activation in mitral stenosis, atrial fibrillation, and cardiomyopathy[J].Clin Cardiol, 1997, 20(1):7-10.
[17] Feinberg WM, Macy E, Cornell ES, et al.Plasminalpha2-antiplasmin complex in patients with atrial fibrillation.Stroke prevention in atrial fibrillation investigators[J].Thromb Haemost, 1999, 82(1):100-103.